Yes‐associated protein 1 and transcriptional coactivator with PDZ‐binding motif activate the mammalian target of rapamycin complex 1 pathway by regulating amino acid transporters in hepatocellular carcinoma
Metabolic activation is a common feature of many cancer cells and is frequently associated with the clinical outcomes of various cancers, including hepatocellular carcinoma. Thus, aberrantly activated metabolic pathways in cancer cells are attractive targets for cancer therapy. Yes‐associated protei...
Saved in:
Published in | Hepatology (Baltimore, Md.) Vol. 63; no. 1; pp. 159 - 172 |
---|---|
Main Authors | , , , , , , , , , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
Wolters Kluwer Health, Inc
01.01.2016
|
Subjects | |
Online Access | Get full text |
ISSN | 0270-9139 1527-3350 |
DOI | 10.1002/hep.28223 |
Cover
Abstract | Metabolic activation is a common feature of many cancer cells and is frequently associated with the clinical outcomes of various cancers, including hepatocellular carcinoma. Thus, aberrantly activated metabolic pathways in cancer cells are attractive targets for cancer therapy. Yes‐associated protein 1 (YAP1) and transcriptional coactivator with PDZ‐binding motif (TAZ) are oncogenic downstream effectors of the Hippo tumor suppressor pathway, which is frequently inactivated in many cancers. Our study revealed that YAP1/TAZ regulates amino acid metabolism by up‐regulating expression of the amino acid transporters solute carrier family 38 member 1 (SLC38A1) and solute carrier family 7 member 5 (SLC7A5). Subsequently, increased uptake of amino acids by the transporters (SLC38A1 and SLC7A5) activates mammalian target of rapamycin complex 1 (mTORC1), a master regulator of cell growth, and stimulates cell proliferation. We also show that high expression of SLC38A1 and SLC7A5 is significantly associated with shorter survival in hepatocellular carcinoma patients. Furthermore, inhibition of the transporters and mTORC1 significantly blocks YAP1/TAZ‐mediated tumorigenesis in the liver. These findings elucidate regulatory networks connecting the Hippo pathway to mTORC1 through amino acid metabolism and the mechanism's potential clinical implications for treating hepatocellular carcinoma. Conclusion: YAP1 and TAZ regulate cancer metabolism and mTORC1 through regulation of amino acid transportation, and two amino acid transporters, SLC38A1 and SLC7A5, might be important therapeutic targets. (Hepatology 2016;63:159–172) |
---|---|
AbstractList | Metabolic activation is a common feature of many cancer cells and is frequently associated with the clinical outcomes of various cancers, including hepatocellular carcinoma. Thus, aberrantly activated metabolic pathways in cancer cells are attractive targets for cancer therapy. Yes-associated protein 1 (YAP1) and transcriptional coactivator with PDZ-binding motif (TAZ) are oncogenic downstream effectors of the Hippo tumor suppressor pathway, which is frequently inactivated in many cancers. Our study revealed that YAP1/TAZ regulates amino acid metabolism by up-regulating expression of the amino acid transporters solute carrier family 38 member 1 (SLC38A1) and solute carrier family 7 member 5 (SLC7A5). Subsequently, increased uptake of amino acids by the transporters (SLC38A1 and SLC7A5) activates mammalian target of rapamycin complex 1 (mTORC1), a master regulator of cell growth, and stimulates cell proliferation. We also show that high expression of SLC38A1 and SLC7A5 is significantly associated with shorter survival in hepatocellular carcinoma patients. Furthermore, inhibition of the transporters and mTORC1 significantly blocks YAP1/TAZ-mediated tumorigenesis in the liver. These findings elucidate regulatory networks connecting the Hippo pathway to mTORC1 through amino acid metabolism and the mechanism's potential clinical implications for treating hepatocellular carcinoma.
YAP1 and TAZ regulate cancer metabolism and mTORC1 through regulation of amino acid transportation, and two amino acid transporters, SLC38A1 and SLC7A5, might be important therapeutic targets. Metabolic activation is a common feature of many cancer cells and is frequently associated with the clinical outcomes of various cancers, including hepatocellular carcinoma. Thus, aberrantly activated metabolic pathways in cancer cells are attractive targets for cancer therapy. Yes-associated protein 1 (YAP1) and transcriptional coactivator with PDZ-binding motif (TAZ) are oncogenic downstream effectors of the Hippo tumor suppressor pathway, which is frequently inactivated in many cancers. Our study revealed that YAP1/TAZ regulates amino acid metabolism by up-regulating expression of the amino acid transporters solute carrier family 38 member 1 (SLC38A1) and solute carrier family 7 member 5 (SLC7A5). Subsequently, increased uptake of amino acids by the transporters (SLC38A1 and SLC7A5) activates mammalian target of rapamycin complex 1 (mTORC1), a master regulator of cell growth, and stimulates cell proliferation. We also show that high expression of SLC38A1 and SLC7A5 is significantly associated with shorter survival in hepatocellular carcinoma patients. Furthermore, inhibition of the transporters and mTORC1 significantly blocks YAP1/TAZ-mediated tumorigenesis in the liver. These findings elucidate regulatory networks connecting the Hippo pathway to mTORC1 through amino acid metabolism and the mechanism's potential clinical implications for treating hepatocellular carcinoma. Conclusion: YAP1 and TAZ regulate cancer metabolism and mTORC1 through regulation of amino acid transportation, and two amino acid transporters, SLC38A1 and SLC7A5, might be important therapeutic targets. (Hepatology 2016;63:159-172) UNLABELLEDMetabolic activation is a common feature of many cancer cells and is frequently associated with the clinical outcomes of various cancers, including hepatocellular carcinoma. Thus, aberrantly activated metabolic pathways in cancer cells are attractive targets for cancer therapy. Yes-associated protein 1 (YAP1) and transcriptional coactivator with PDZ-binding motif (TAZ) are oncogenic downstream effectors of the Hippo tumor suppressor pathway, which is frequently inactivated in many cancers. Our study revealed that YAP1/TAZ regulates amino acid metabolism by up-regulating expression of the amino acid transporters solute carrier family 38 member 1 (SLC38A1) and solute carrier family 7 member 5 (SLC7A5). Subsequently, increased uptake of amino acids by the transporters (SLC38A1 and SLC7A5) activates mammalian target of rapamycin complex 1 (mTORC1), a master regulator of cell growth, and stimulates cell proliferation. We also show that high expression of SLC38A1 and SLC7A5 is significantly associated with shorter survival in hepatocellular carcinoma patients. Furthermore, inhibition of the transporters and mTORC1 significantly blocks YAP1/TAZ-mediated tumorigenesis in the liver. These findings elucidate regulatory networks connecting the Hippo pathway to mTORC1 through amino acid metabolism and the mechanism's potential clinical implications for treating hepatocellular carcinoma.CONCLUSIONYAP1 and TAZ regulate cancer metabolism and mTORC1 through regulation of amino acid transportation, and two amino acid transporters, SLC38A1 and SLC7A5, might be important therapeutic targets. Metabolic activation is a common feature of many cancer cells and is frequently associated with the clinical outcomes of various cancers, including hepatocellular carcinoma. Thus, aberrantly activated metabolic pathways in cancer cells are attractive targets for cancer therapy. Yes‐associated protein 1 (YAP1) and transcriptional coactivator with PDZ‐binding motif (TAZ) are oncogenic downstream effectors of the Hippo tumor suppressor pathway, which is frequently inactivated in many cancers. Our study revealed that YAP1 / TAZ regulates amino acid metabolism by up‐regulating expression of the amino acid transporters solute carrier family 38 member 1 ( SLC38A1 ) and solute carrier family 7 member 5 ( SLC7A5 ). Subsequently, increased uptake of amino acids by the transporters ( SLC38A1 and SLC7A5 ) activates mammalian target of rapamycin complex 1 (mTORC1), a master regulator of cell growth, and stimulates cell proliferation. We also show that high expression of SLC38A1 and SLC7A5 is significantly associated with shorter survival in hepatocellular carcinoma patients. Furthermore, inhibition of the transporters and mTORC1 significantly blocks YAP1/TAZ‐mediated tumorigenesis in the liver. These findings elucidate regulatory networks connecting the Hippo pathway to mTORC1 through amino acid metabolism and the mechanism's potential clinical implications for treating hepatocellular carcinoma. Conclusion: YAP1 and TAZ regulate cancer metabolism and mTORC1 through regulation of amino acid transportation, and two amino acid transporters, SLC38A1 and SLC7A5, might be important therapeutic targets. (H epatology 2016;63:159–172) |
Author | Rodriguez‐Aguayo, Cristian Lopez‐Berestein, Gabriel Johnson, Randy L. Kim, Ji Hoon Kang, Myoung‐Hee Hwang, Jun Eul Jang, Hee‐Jin Mangala, Lingegowda S. Sood, Anil K. Lee, Ju‐Seog Kim, Sang Bae Shim, Jae‐Jun Park, Yun‐Yong Jeong, Woojin Yoo, Jeong Eun Lee, Hyun‐Sung Sohn, Bo Hwa Pradeep, Sunila Park, Inn Sun Rupaimoole, Rajesha Park, Young Nyun Mills, Gordon B. |
Author_xml | – sequence: 1 givenname: Yun‐Yong surname: Park fullname: Park, Yun‐Yong organization: University of Ulsan College of Medicine – sequence: 2 givenname: Bo Hwa surname: Sohn fullname: Sohn, Bo Hwa organization: The University of Texas MD Anderson Cancer Center – sequence: 3 givenname: Randy L. surname: Johnson fullname: Johnson, Randy L. organization: The University of Texas MD Anderson Cancer Center – sequence: 4 givenname: Myoung‐Hee surname: Kang fullname: Kang, Myoung‐Hee organization: University of Ulsan College of Medicine – sequence: 5 givenname: Sang Bae surname: Kim fullname: Kim, Sang Bae organization: The University of Texas MD Anderson Cancer Center – sequence: 6 givenname: Jae‐Jun surname: Shim fullname: Shim, Jae‐Jun organization: Kyung Hee University – sequence: 7 givenname: Lingegowda S. surname: Mangala fullname: Mangala, Lingegowda S. organization: The University of Texas MD Anderson Cancer Center – sequence: 8 givenname: Ji Hoon surname: Kim fullname: Kim, Ji Hoon organization: Korea University College of Medicine – sequence: 9 givenname: Jeong Eun surname: Yoo fullname: Yoo, Jeong Eun organization: Yonsei University College of Medicine – sequence: 10 givenname: Cristian surname: Rodriguez‐Aguayo fullname: Rodriguez‐Aguayo, Cristian organization: The University of Texas MD Anderson Cancer Center – sequence: 11 givenname: Sunila surname: Pradeep fullname: Pradeep, Sunila organization: The University of Texas MD Anderson Cancer Center – sequence: 12 givenname: Jun Eul surname: Hwang fullname: Hwang, Jun Eul organization: The University of Texas MD Anderson Cancer Center – sequence: 13 givenname: Hee‐Jin surname: Jang fullname: Jang, Hee‐Jin organization: The University of Texas MD Anderson Cancer Center – sequence: 14 givenname: Hyun‐Sung surname: Lee fullname: Lee, Hyun‐Sung organization: The University of Texas MD Anderson Cancer Center – sequence: 15 givenname: Rajesha surname: Rupaimoole fullname: Rupaimoole, Rajesha organization: The University of Texas MD Anderson Cancer Center – sequence: 16 givenname: Gabriel surname: Lopez‐Berestein fullname: Lopez‐Berestein, Gabriel organization: The University of Texas MD Anderson Cancer Center – sequence: 17 givenname: Woojin surname: Jeong fullname: Jeong, Woojin organization: Ewha Woman's University – sequence: 18 givenname: Inn Sun surname: Park fullname: Park, Inn Sun organization: The University of Texas MD Anderson Cancer Center – sequence: 19 givenname: Young Nyun surname: Park fullname: Park, Young Nyun organization: Yonsei University College of Medicine – sequence: 20 givenname: Anil K. surname: Sood fullname: Sood, Anil K. organization: The University of Texas MD Anderson Cancer Center – sequence: 21 givenname: Gordon B. surname: Mills fullname: Mills, Gordon B. organization: The University of Texas MD Anderson Cancer Center – sequence: 22 givenname: Ju‐Seog surname: Lee fullname: Lee, Ju‐Seog organization: The University of Texas MD Anderson Cancer Center |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/26389641$$D View this record in MEDLINE/PubMed |
BookMark | eNqNkk1uFDEQhS0URH5gwQWQJTawmMQ_3dPtJQqBIEUiC1jAplXtLs84atuN7ckwO47A2TgCJ8HDDCwiEbGwvPneq6pXdUwOfPBIyFPOTjlj4myJ06lohZAPyBGvRTOTsmYH5IiJhs0Ul-qQHKd0wxhTlWgfkUMxl62aV_yI_PiE6ee375BS0BYyDnSKIaP1lFPwA80RfNLRTtkGDyPVAXS2t5BDpGubl_T69eei760frF9QF7I1dI8gzUukDpyD0YKnGeICMw2GRpjAbXSpooObRvxaqk2Ql2vY0H5DIy5WI-StITjrQzG0-1amEDPGRIu0TF3a0DiOBY5UQyyGwcFj8tDAmPDJ_j8hH99cfDi_nF29f_vu_NXVTNdcydnAtBYSAQajse8rGERVI-hGSs5Ub9pGGJSmVgZaUxnZ9hyGEi6WJ9tByhPyYudbEvuywpQ7Z9O2HfAYVqnjTTOfz6u6Vf-B1rxqFeNb9Pkd9CasYom-UIqX_VVSyXuppmYVbxlnhXq2p1a9w6GbonUQN92f9Rfg5Q7QMaQU0fxFOOu2p9WVkLvfp1XYszusthm2Z1EWY8f7FGs74ubf1t3lxfVO8Que8OXN |
CODEN | HPTLD9 |
CitedBy_id | crossref_primary_10_1177_2472630317698683 crossref_primary_10_1016_j_tcb_2019_10_005 crossref_primary_10_3389_fonc_2020_00928 crossref_primary_10_3389_fonc_2019_01163 crossref_primary_10_3390_cells8040370 crossref_primary_10_1038_s41467_019_09597_w crossref_primary_10_1146_annurev_cancerbio_030617_050202 crossref_primary_10_18632_aging_102714 crossref_primary_10_3390_v15020324 crossref_primary_10_1016_j_celrep_2020_108609 crossref_primary_10_1016_j_bbcan_2019_03_001 crossref_primary_10_1186_s13062_024_00475_0 crossref_primary_10_15252_embj_2018100294 crossref_primary_10_1016_j_ccell_2021_06_016 crossref_primary_10_3390_microorganisms9010007 crossref_primary_10_1002_adfm_202412705 crossref_primary_10_1002_mco2_340 crossref_primary_10_3390_biomedicines10102512 crossref_primary_10_1158_0008_5472_CAN_23_2994 crossref_primary_10_3390_genes13091585 crossref_primary_10_1002_hep_32490 crossref_primary_10_1038_s41467_022_34559_0 crossref_primary_10_1186_s13046_018_0806_3 crossref_primary_10_15252_embj_2021109365 crossref_primary_10_3724_abbs_2023035 crossref_primary_10_1007_s00253_024_13122_5 crossref_primary_10_1016_j_semcancer_2017_10_007 crossref_primary_10_1158_1535_7163_MCT_21_0071 crossref_primary_10_1016_j_gendis_2019_11_003 crossref_primary_10_1210_endrev_bnac013 crossref_primary_10_1016_j_pharmthera_2017_12_011 crossref_primary_10_1051_fopen_2019023 crossref_primary_10_15252_embr_201643577 crossref_primary_10_3389_fgene_2021_771810 crossref_primary_10_1038_s41598_024_54658_w crossref_primary_10_1097_FJC_0000000000000736 crossref_primary_10_3389_fcell_2023_1291686 crossref_primary_10_1016_j_canlet_2019_07_015 crossref_primary_10_1155_2023_4364654 crossref_primary_10_1053_j_gastro_2016_10_047 crossref_primary_10_1038_s41467_018_04179_8 crossref_primary_10_1091_mbc_E18_02_0141 crossref_primary_10_3389_fonc_2022_937957 crossref_primary_10_1016_j_cmet_2018_07_010 crossref_primary_10_1038_nrgastro_2016_59 crossref_primary_10_3389_fendo_2024_1344971 crossref_primary_10_1002_mco2_70128 crossref_primary_10_1126_scisignal_aan4667 crossref_primary_10_1016_j_phrs_2019_03_018 crossref_primary_10_1038_s12276_018_0174_2 crossref_primary_10_1042_BSR20171072 crossref_primary_10_1016_j_bioorg_2024_107212 crossref_primary_10_3390_cancers15010186 crossref_primary_10_1038_labinvest_2017_70 crossref_primary_10_1038_s41419_018_1142_4 crossref_primary_10_1038_s41467_018_07394_5 crossref_primary_10_1016_j_celrep_2024_115128 crossref_primary_10_3389_fimmu_2021_624324 crossref_primary_10_1038_s41419_020_02994_w crossref_primary_10_3389_fmed_2023_1029021 crossref_primary_10_1016_j_drudis_2021_03_004 crossref_primary_10_3748_wjg_v25_i15_1797 crossref_primary_10_1161_CIRCRESAHA_118_314187 crossref_primary_10_1007_s12094_022_02977_7 crossref_primary_10_3892_ijo_2024_5676 crossref_primary_10_3389_fimmu_2024_1377722 crossref_primary_10_1038_s41575_021_00571_w crossref_primary_10_3390_cells9102308 crossref_primary_10_1038_s41419_023_05598_2 crossref_primary_10_3390_cells7050037 crossref_primary_10_1016_j_ydbio_2020_12_018 crossref_primary_10_1016_j_apsb_2021_09_019 crossref_primary_10_1002_1878_0261_12999 crossref_primary_10_18632_oncotarget_20622 crossref_primary_10_3389_fcell_2024_1335636 crossref_primary_10_1038_s41580_021_00386_2 crossref_primary_10_1096_fj_202002284RR crossref_primary_10_3390_cells8060600 crossref_primary_10_1128_MCB_00596_20 crossref_primary_10_1002_hep4_1278 crossref_primary_10_1158_1541_7786_MCR_18_0313 crossref_primary_10_1038_s41556_021_00781_z crossref_primary_10_1038_s42255_022_00584_y crossref_primary_10_1016_j_bbcan_2022_188787 crossref_primary_10_1002_mco2_375 crossref_primary_10_1016_j_devcel_2020_06_025 crossref_primary_10_3390_cells9092002 crossref_primary_10_1038_ncb3389 crossref_primary_10_1002_hsr2_70343 crossref_primary_10_3390_cells10061416 crossref_primary_10_1016_j_isci_2024_111447 crossref_primary_10_3390_cancers11111648 crossref_primary_10_3389_fphys_2017_00942 crossref_primary_10_1007_s11154_022_09768_z crossref_primary_10_1186_s12967_024_05027_8 crossref_primary_10_1016_j_bcp_2022_115074 crossref_primary_10_3390_cancers14092151 crossref_primary_10_3389_fphar_2024_1345522 crossref_primary_10_1016_j_molmet_2024_101952 crossref_primary_10_1038_emm_2017_166 crossref_primary_10_1038_s41467_024_55769_8 crossref_primary_10_1002_mef2_59 crossref_primary_10_1158_1541_7786_MCR_19_0756 crossref_primary_10_18632_oncotarget_22666 crossref_primary_10_3389_fonc_2021_631991 crossref_primary_10_1158_1078_0432_CCR_15_2468 crossref_primary_10_1007_s00018_019_03085_6 crossref_primary_10_1016_j_ajpath_2021_05_017 crossref_primary_10_1038_cr_2015_140 crossref_primary_10_3390_ijms24066006 |
Cites_doi | 10.1073/pnas.0912203107 10.1242/dev.045500 10.1073/pnas.0911427107 10.1146/annurev-cellbio-092910-154237 10.1016/j.ccr.2009.09.026 10.1113/expphysiol.1990.sp003382 10.1016/j.tibs.2010.05.003 10.1016/j.cell.2008.11.044 10.1016/j.cell.2007.07.019 10.1002/emmm.201100187 10.1002/hep.24813 10.1006/taap.1998.8555 10.1111/cas.12587 10.1074/jbc.M305597200 10.1371/journal.pone.0075449 10.1038/onc.2009.358 10.1007/s12032-009-9201-4 10.1053/j.gastro.2008.08.008 10.1016/j.ccr.2014.01.010 10.1007/s11912-012-0227-y 10.1101/gad.192856.112 10.1073/pnas.0911409107 10.1038/nrc2981 10.1002/hep.510300212 10.1111/j.2517-6161.1972.tb00899.x 10.1111/cas.12085 10.1002/cncr.24495 10.1101/gad.1664408 10.1016/j.cub.2007.10.039 10.1046/j.1432-1033.2002.03069.x 10.3322/CA.2007.0010 10.1016/j.cell.2006.05.030 10.1038/nrc3458 10.1002/hep.27388 10.1038/nrd3504 10.1038/ncb2615 10.1101/gad.1536007 10.1042/BJ20101912 10.1074/jbc.273.23.14484 10.1038/nrm2221 10.1038/nrgastro.2014.10 10.1002/jcb.25117 10.1158/1078-0432.CCR-12-2587 10.1016/0304-4157(83)90003-5 10.1016/j.mam.2012.07.015 |
ContentType | Journal Article |
Copyright | 2015 by the American Association for the Study of Liver Diseases 2015 by the American Association for the Study of Liver Diseases. 2016 by the American Association for the Study of Liver Diseases |
Copyright_xml | – notice: 2015 by the American Association for the Study of Liver Diseases – notice: 2015 by the American Association for the Study of Liver Diseases. – notice: 2016 by the American Association for the Study of Liver Diseases |
DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7T5 7TM 7TO 7U9 H94 K9. 7X8 |
DOI | 10.1002/hep.28223 |
DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Immunology Abstracts Nucleic Acids Abstracts Oncogenes and Growth Factors Abstracts Virology and AIDS Abstracts AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) MEDLINE - Academic |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Immunology Abstracts Virology and AIDS Abstracts Oncogenes and Growth Factors Abstracts Nucleic Acids Abstracts MEDLINE - Academic |
DatabaseTitleList | MEDLINE AIDS and Cancer Research Abstracts AIDS and Cancer Research Abstracts MEDLINE - Academic CrossRef AIDS and Cancer Research Abstracts |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1527-3350 |
EndPage | 172 |
ExternalDocumentID | 3900918221 26389641 10_1002_hep_28223 HEP28223 |
Genre | article Research Support, Non-U.S. Gov't Journal Article Research Support, N.I.H., Extramural |
GrantInformation_xml | – fundername: The 2011 and 2012 cycles of The University of Texas MD Anderson Cancer Center's Sister Institute Network Fund (to J.‐S.L.) funderid: 5U54 CA112970‐08 (to G.B.M.) ; 5P01CA099031‐07 (to G.B.M.) ; P30 CA016672 (to G.B.M.) – fundername: The National Research Foundation of Korea. funderid: Bio R&D Program Grant M10642040002‐07N4204‐00210 (to W.J.) ; 2011‐0018055 (to W.J.) ; NRF‐2013R1A2A2A05005990 (to Y.N.P.) ; NRF‐2014R1A1A2053529 (to Y.‐Y.P) – fundername: The National Institutes of Health funderid: MD Anderson Cancer Center's Support Grant (CA016672) – fundername: NCI NIH HHS grantid: U54 CA112970 – fundername: NCI NIH HHS grantid: P30 CA016672 – fundername: NCI NIH HHS grantid: 5P01CA099031-07 – fundername: NCI NIH HHS grantid: CA016672 – fundername: NIDDK NIH HHS grantid: R01 DK102611 – fundername: NCI NIH HHS grantid: 5U54 CA112970-08 – fundername: NCI NIH HHS grantid: R01 CA150229 – fundername: NCI NIH HHS grantid: P01 CA099031 |
GroupedDBID | --- --K .3N .55 .GA .GJ .Y3 05W 0R~ 10A 186 1B1 1CY 1L6 1OC 1ZS 1~5 31~ 33P 3O- 3SF 3WU 4.4 4G. 4ZD 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52S 52T 52U 52V 52W 52X 53G 5GY 5RE 5VS 7-5 702 7PT 8-0 8-1 8-3 8-4 8-5 8UM 930 A01 A03 AAEDT AAESR AAEVG AAHHS AALRI AANHP AAONW AAQFI AAQQT AAQXK AASGY AAXRX AAXUO AAZKR ABCQN ABCUV ABEML ABIJN ABJNI ABLJU ABMAC ABOCM ABPVW ABWVN ABXGK ACAHQ ACBWZ ACCFJ ACCZN ACGFS ACLDA ACMXC ACPOU ACPRK ACRPL ACSCC ACXBN ACXQS ACYXJ ACZKN ADBBV ADEOM ADIZJ ADKYN ADMGS ADMUD ADNMO ADOZA ADXAS ADZMN ADZOD AECAP AEEZP AEIMD AENEX AEQDE AFBPY AFFNX AFGKR AFNMH AFUWQ AFZJQ AGQPQ AHMBA AHQVU AIACR AIURR AIWBW AJAOE AJBDE ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN AMBMR AMYDB ASPBG ATUGU AVWKF AZBYB AZFZN AZVAB BAFTC BAWUL BDRZF BHBCM BMXJE BROTX BRXPI BY8 C45 CAG COF CS3 D-6 D-7 D-E D-F DCZOG DIK DPXWK DR2 DRFUL DRMAN DRSTM DU5 E3Z EBS EJD F00 F01 F04 F5P FD8 FDB FEDTE FGOYB FUBAC G-S G.N GNP GODZA H.X HBH HF~ HHY HHZ HVGLF HZ~ IHE IX1 J0M J5H JPC KBYEO KQQ LATKE LC2 LC3 LEEKS LH4 LITHE LOXES LP6 LP7 LUTES LW6 LYRES M41 M65 MEWTI MJL MK4 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM N04 N05 N4W N9A NF~ NNB NQ- O66 O9- OIG OK1 OVD P2P P2W P2X P2Z P4B P4D PALCI PQQKQ Q.N Q11 QB0 QRW R.K R2- RIG RIWAO RJQFR ROL RPZ RX1 RYL SEW SSZ SUPJJ TEORI UB1 V2E V9Y W2D W8V W99 WBKPD WH7 WHWMO WIB WIH WIJ WIK WJL WOHZO WQJ WVDHM WXI WXSBR X7M XG1 XV2 ZGI ZXP ZZTAW ~IA ~WT AAYXX CITATION ACIJW CGR CUY CVF ECM EIF NPM 7T5 7TM 7TO 7U9 AAMMB ADSXY AEFGJ AGXDD AIDQK AIDYY H94 K9. 7X8 |
ID | FETCH-LOGICAL-c5193-d0cc23eaadfcebb4ad245eac733109bf872fe3f59fa8f4f38b1ad527e52738d33 |
IEDL.DBID | DR2 |
ISSN | 0270-9139 |
IngestDate | Thu Sep 04 19:19:16 EDT 2025 Thu Sep 04 15:43:30 EDT 2025 Wed Aug 13 10:42:03 EDT 2025 Wed Aug 13 10:39:24 EDT 2025 Thu Apr 03 07:01:45 EDT 2025 Tue Jul 01 03:33:43 EDT 2025 Thu Apr 24 22:56:25 EDT 2025 Thu Apr 24 03:18:00 EDT 2025 |
IsDoiOpenAccess | false |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 1 |
Language | English |
License | 2015 by the American Association for the Study of Liver Diseases. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c5193-d0cc23eaadfcebb4ad245eac733109bf872fe3f59fa8f4f38b1ad527e52738d33 |
Notes | Supported in part by the 2011 and 2012 cycles of The University of Texas MD Anderson Cancer Center's Sister Institute Network Fund (to J.‐S.L.); 5U54 CA112970‐08 (to G.B.M.), 5P01CA099031‐07 (to G.B.M.), and P30 CA016672 (to G.B.M.); MD Anderson Cancer Center's Support Grant (CA016672) from the National Institutes of Health; Bio R&D Program Grant 2014R1A2A2A01003983 (to W.J.); and 2011‐0018055 (to W.J.), NRF‐2013R1A2A2A05005990 (to Y.N.P.), and NRF‐2014R1A1A2053529 (to Y.‐Y.P) from the National Research Foundation of Korea. Potential conflict of interest: Nothing to report. ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
OpenAccessLink | https://aasldpubs.onlinelibrary.wiley.com/doi/pdfdirect/10.1002/hep.28223 |
PMID | 26389641 |
PQID | 1750418010 |
PQPubID | 996352 |
PageCount | 14 |
ParticipantIDs | proquest_miscellaneous_1776664589 proquest_miscellaneous_1751489019 proquest_journals_1919424393 proquest_journals_1750418010 pubmed_primary_26389641 crossref_primary_10_1002_hep_28223 crossref_citationtrail_10_1002_hep_28223 wiley_primary_10_1002_hep_28223_HEP28223 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | January 2016 |
PublicationDateYYYYMMDD | 2016-01-01 |
PublicationDate_xml | – month: 01 year: 2016 text: January 2016 |
PublicationDecade | 2010 |
PublicationPlace | United States |
PublicationPlace_xml | – name: United States – name: Hoboken |
PublicationTitle | Hepatology (Baltimore, Md.) |
PublicationTitleAlternate | Hepatology |
PublicationYear | 2016 |
Publisher | Wolters Kluwer Health, Inc |
Publisher_xml | – name: Wolters Kluwer Health, Inc |
References | 2011; 138 2007; 17 1990; 75 2009; 87 2011; 436 2010; 35 2010; 107 2013; 104 2008; 58 2011; 11 2014; 25 2011; 10 2012; 18 2014; 2014 2015; 106 2007; 31 2012; 14 2013; 8 2003; 278 2012; 55 1983; 737 2009; 136 2009; 115 1998; 273 2010; 27 2015; 116 2013; 13 2010; 29 2015; 61 2013; 34 2007; 130 2005; 326 2007; 8 1999; 154 2002; 269 2008; 22 1999; 30 2008; 135 2012; 26 2007; 21 2011; 27 2012; 4 1972; 34 2012; 5 2009; 16 2014; 11 2006; 125 (hep28223-bib-0033-20241017) 2002; 269 (hep28223-bib-0015-20241017) 2015; 61 (hep28223-bib-0038-20241017) 2013; 8 (hep28223-bib-0004-20241017) 2007; 8 (hep28223-bib-0028-20241017) 1990; 75 (hep28223-bib-0016-20241017) 2008; 58 (hep28223-bib-0010-20241017) 2009; 16 (hep28223-bib-0042-20241017) 1999; 154 (hep28223-bib-0011-20241017) 2013; 13 (hep28223-bib-0021-20241017) 2011; 11 (hep28223-bib-0041-20241017) 2010; 27 (hep28223-bib-0048-20241017) 2012; 14 (hep28223-bib-0043-20241017) 2012; 5 (hep28223-bib-0005-20241017) 2006; 125 (hep28223-bib-0025-20241017) 2009; 87 (hep28223-bib-0024-20241017) 2011; 436 (hep28223-bib-0046-20241017) 2012; 26 (hep28223-bib-0002-20241017) 2007; 21 (hep28223-bib-0007-20241017) 2010; 107 (hep28223-bib-0032-20241017) 2009; 136 (hep28223-bib-0003-20241017) 2007; 130 (hep28223-bib-0044-20241017) 2007; 31 (hep28223-bib-0018-20241017) 2012; 4 (hep28223-bib-0029-20241017) 1983; 737 (hep28223-bib-0036-20241017) 2015; 106 (hep28223-bib-0035-20241017) 2015; 116 (hep28223-bib-0012-20241017) 2011; 10 (hep28223-bib-0020-20241017) 1972; 34 (hep28223-bib-0039-20241017) 2014; 2014 (hep28223-bib-0030-20241017) 1998; 273 (hep28223-bib-0040-20241017) 2008; 135 (hep28223-bib-0006-20241017) 2007; 17 (hep28223-bib-0019-20241017) 2003; 278 (hep28223-bib-0027-20241017) 2010; 35 (hep28223-bib-0031-20241017) 2005; 326 (hep28223-bib-0014-20241017) 2012; 18 (hep28223-bib-0037-20241017) 2009; 115 (hep28223-bib-0001-20241017) 2011; 138 (hep28223-bib-0008-20241017) 2010; 107 (hep28223-bib-0045-20241017) 2012; 14 (hep28223-bib-0047-20241017) 2014; 25 (hep28223-bib-0049-20241017) 1999; 30 (hep28223-bib-0017-20241017) 2014; 11 (hep28223-bib-0023-20241017) 2008; 22 (hep28223-bib-0026-20241017) 2010; 29 (hep28223-bib-0013-20241017) 2013; 104 (hep28223-bib-0009-20241017) 2010; 107 (hep28223-bib-0050-20241017) 2013; 34 (hep28223-bib-0034-20241017) 2012; 55 (hep28223-bib-0022-20241017) 2011; 27 |
References_xml | – volume: 22 start-page: 1962 year: 2008 end-page: 1971 article-title: TEAD mediates YAP‐dependent gene induction and growth control publication-title: Genes Dev – volume: 130 start-page: 1120 year: 2007 end-page: 1133 article-title: Elucidation of a universal size‐control mechanism in and mammals publication-title: Cell – volume: 107 start-page: 1437 year: 2010 end-page: 1442 article-title: Hippo signaling is a potent growth and tumor suppressor pathway in the mammalian liver publication-title: Proc Natl Acad Sci USA – volume: 58 start-page: 71 year: 2008 end-page: 96 article-title: Cancer statistics, 2008 publication-title: CA Cancer J Clin – volume: 10 start-page: 671 year: 2011 end-page: 684 article-title: Targeting cancer metabolism: a therapeutic window opens publication-title: Nat Rev Drug Discov – volume: 5 start-page: 410 year: 2012 end-page: 414 article-title: Differences in Yes‐associated protein and mRNA levels in regenerating liver and hepatocellular carcinoma publication-title: Mol Med Report – volume: 326 start-page: 174 year: 2005 end-page: 180 article-title: Glutamine is a key regulator for amino acid‐controlled cell growth through the mTOR signaling pathway in rat intestinal epithelial cells publication-title: Biochem Biophys Res Commun – volume: 26 start-page: 1300 year: 2012 end-page: 1305 article-title: Genetic and pharmacological disruption of the TEAD‐YAP complex suppresses the oncogenic activity of YAP publication-title: Genes Dev – volume: 154 start-page: 84 year: 1999 end-page: 96 article-title: TA1 oncofetal rat liver cDNA and putative amino acid permease: temporal correlation with c‐myc during acute CCl liver injury and variation of RNA levels in response to amino acids in hepatocyte cultures publication-title: Toxicol Appl Pharmacol – volume: 61 start-page: 191 year: 2015 end-page: 199 article-title: Emerging trends in hepatocellular carcinoma incidence and mortality publication-title: Hepatology – volume: 136 start-page: 521 year: 2009 end-page: 534 article-title: Bidirectional transport of amino acids regulates mTOR and autophagy publication-title: Cell – volume: 14 start-page: 1322 year: 2012 end-page: 1329 article-title: YAP mediates crosstalk between the Hippo and PI(3)K‐TOR pathways by suppressing PTEN via miR‐29 publication-title: Nat Cell Biol – volume: 75 start-page: 3 year: 1990 end-page: 26 article-title: The identification of neutral amino acid transport systems publication-title: Exp Physiol – volume: 135 start-page: 1972 year: 2008 end-page: 1983 article-title: Pivotal role of mTOR signaling in hepatocellular carcinoma publication-title: Gastroenterology – volume: 11 start-page: 447 year: 2014 end-page: 452 article-title: HCC therapies—lessons learned publication-title: Nat Rev Gastroenterol Hepatol – volume: 138 start-page: 9 year: 2011 end-page: 22 article-title: Hippo signaling: growth control and beyond publication-title: Development – volume: 29 start-page: 313 year: 2010 end-page: 324 article-title: Q's next: the diverse functions of glutamine in metabolism, cell biology and cancer publication-title: Oncogene – volume: 17 start-page: 2054 year: 2007 end-page: 2060 article-title: YAP1 increases organ size and expands undifferentiated progenitor cells publication-title: Curr Biol – volume: 16 start-page: 425 year: 2009 end-page: 438 article-title: Mst1 and Mst2 maintain hepatocyte quiescence and suppress hepatocellular carcinoma development through inactivation of the Yap1 oncogene publication-title: Cancer Cell – volume: 278 start-page: 33334 year: 2003 end-page: 33341 article-title: WW domain‐containing protein YAP associates with ErbB‐4 and acts as a co‐transcriptional activator for the carboxyl‐terminal fragment of ErbB‐4 that translocates to the nucleus publication-title: J Biol Chem – volume: 35 start-page: 427 year: 2010 end-page: 433 article-title: Glutamine addiction: a new therapeutic target in cancer publication-title: Trends Biochem Sci – volume: 55 start-page: 1443 year: 2012 end-page: 1452 article-title: 65‐gene‐based risk score classifier predicts overall survival in hepatocellular carcinoma publication-title: Hepatology – volume: 14 start-page: 129 year: 2012 end-page: 138 article-title: PI3K and mTOR signaling pathways in cancer: new data on targeted therapies publication-title: Curr Oncol Rep – volume: 737 start-page: 267 year: 1983 end-page: 284 article-title: The regulation of neutral amino acid transport in mammalian cells publication-title: Biochim Biophys Acta – volume: 115 start-page: 4576 year: 2009 end-page: 4585 article-title: Yes‐associated protein is an independent prognostic marker in hepatocellular carcinoma publication-title: Cancer – volume: 34 start-page: 702 year: 2013 end-page: 710 article-title: Solute carriers as drug targets: current use, clinical trials and prospective publication-title: Mol Aspects Med – volume: 116 start-page: 2465 year: 2015 end-page: 2475 article-title: Functional and clinical evidence that TAZ is a candidate oncogene in hepatocellular carcinoma publication-title: J Cell Biochem – volume: 106 start-page: 151 year: 2015 end-page: 159 article-title: TAZ regulates cell proliferation and epithelial‐mesenchymal transition of human hepatocellular carcinoma publication-title: Cancer Sci – volume: 104 start-page: 275 year: 2013 end-page: 281 article-title: Cancer metabolism: key players in metabolic reprogramming publication-title: Cancer Sci – volume: 25 start-page: 166 year: 2014 end-page: 180 article-title: A peptide mimicking VGLL4 function acts as a YAP antagonist therapy against gastric cancer publication-title: Cancer Cell – volume: 87 start-page: 77 year: 2009 end-page: 91 article-title: YAP, TAZ, and Yorkie: a conserved family of signal‐responsive transcriptional coregulators in animal development and human disease publication-title: Biochem Cell Biol – volume: 273 start-page: 14484 year: 1998 end-page: 14494 article-title: Amino acid sufficiency and mTOR regulate p70 S6 kinase and eIF‐4E BP1 through a common effector mechanism publication-title: J Biol Chem – volume: 107 start-page: 8248 year: 2010 end-page: 8253 article-title: The Hippo‐Salvador pathway restrains hepatic oval cell proliferation, liver size, and liver tumorigenesis publication-title: Proc Natl Acad Sci USA – volume: 4 start-page: 52 year: 2012 end-page: 67 article-title: Reconstruction of nuclear receptor network reveals that NR2E3 is a novel upstream regulator of ESR1 in breast cancer publication-title: EMBO Mol Med – volume: 34 start-page: 187 year: 1972 end-page: 220 article-title: Regression models with life tables publication-title: J R Stat Soc – volume: 27 start-page: 255 year: 2010 end-page: 261 article-title: The mTOR pathway is associated with the poor prognosis of human hepatocellular carcinoma publication-title: Med Oncol – volume: 8 start-page: e75449 year: 2013 article-title: Increased expression of Yes‐associated protein 1 in hepatocellular carcinoma with stemness and combined hepatocellular‐cholangiocarcinoma publication-title: PLoS One – volume: 30 start-page: 437 year: 1999 end-page: 444 article-title: Inhibition of system A amino acid transport and hepatocyte proliferation following partial hepatectomy in the rat publication-title: Hepatology – volume: 18 start-page: 5537 year: 2012 end-page: 5545 article-title: Targeting cancer metabolism publication-title: Clin Cancer Res – volume: 125 start-page: 1253 year: 2006 end-page: 1267 article-title: Identification and validation of oncogenes in liver cancer using an integrative oncogenomic approach publication-title: Cell – volume: 11 start-page: 85 year: 2011 end-page: 95 article-title: Regulation of cancer cell metabolism publication-title: Nat Rev Cancer – volume: 27 start-page: 441 year: 2011 end-page: 464 article-title: Aerobic glycolysis: meeting the metabolic requirements of cell proliferation publication-title: Annu Rev Cell Dev Biol – volume: 107 start-page: 1431 year: 2010 end-page: 1436 article-title: Mammalian Mst1 and Mst2 kinases play essential roles in organ size control and tumor suppression publication-title: Proc Natl Acad Sci USA – volume: 13 start-page: 246 year: 2013 end-page: 257 article-title: The Hippo pathway and human cancer publication-title: Nat Rev Cancer – volume: 8 start-page: 613 year: 2007 end-page: 621 article-title: Filling out the Hippo pathway publication-title: Nat Rev Mol Cell Biol – volume: 2014 start-page: 261365 year: 2014 article-title: Expression and clinical significance of YAP, TAZ, and AREG in hepatocellular carcinoma publication-title: J Immunol Res – volume: 31 start-page: 81 year: 2007 end-page: 87 article-title: Activation of a system A amino acid transporter, ATA1/SLC38A1, in human hepatocellular carcinoma and preneoplastic liver tissues publication-title: Int J Oncol – volume: 436 start-page: 193 year: 2011 end-page: 211 article-title: The role of amino acid transporters in inherited and acquired diseases publication-title: Biochem J – volume: 21 start-page: 886 year: 2007 end-page: 897 article-title: Hippo signaling in organ size control publication-title: Genes Dev – volume: 269 start-page: 3742 year: 2002 end-page: 3750 article-title: Signalling pathways and combinatory effects of insulin and amino acids in isolated rat hepatocytes publication-title: Eur J Biochem – volume: 107 start-page: 8248 year: 2010 ident: hep28223-bib-0008-20241017 article-title: The Hippo‐Salvador pathway restrains hepatic oval cell proliferation, liver size, and liver tumorigenesis publication-title: Proc Natl Acad Sci USA doi: 10.1073/pnas.0912203107 – volume: 138 start-page: 9 year: 2011 ident: hep28223-bib-0001-20241017 article-title: Hippo signaling: growth control and beyond publication-title: Development doi: 10.1242/dev.045500 – volume: 107 start-page: 1437 year: 2010 ident: hep28223-bib-0007-20241017 article-title: Hippo signaling is a potent in vivo growth and tumor suppressor pathway in the mammalian liver publication-title: Proc Natl Acad Sci USA doi: 10.1073/pnas.0911427107 – volume: 27 start-page: 441 year: 2011 ident: hep28223-bib-0022-20241017 article-title: Aerobic glycolysis: meeting the metabolic requirements of cell proliferation publication-title: Annu Rev Cell Dev Biol doi: 10.1146/annurev-cellbio-092910-154237 – volume: 16 start-page: 425 year: 2009 ident: hep28223-bib-0010-20241017 article-title: Mst1 and Mst2 maintain hepatocyte quiescence and suppress hepatocellular carcinoma development through inactivation of the Yap1 oncogene publication-title: Cancer Cell doi: 10.1016/j.ccr.2009.09.026 – volume: 2014 start-page: 261365 year: 2014 ident: hep28223-bib-0039-20241017 article-title: Expression and clinical significance of YAP, TAZ, and AREG in hepatocellular carcinoma publication-title: J Immunol Res – volume: 75 start-page: 3 year: 1990 ident: hep28223-bib-0028-20241017 article-title: The identification of neutral amino acid transport systems publication-title: Exp Physiol doi: 10.1113/expphysiol.1990.sp003382 – volume: 35 start-page: 427 year: 2010 ident: hep28223-bib-0027-20241017 article-title: Glutamine addiction: a new therapeutic target in cancer publication-title: Trends Biochem Sci doi: 10.1016/j.tibs.2010.05.003 – volume: 136 start-page: 521 year: 2009 ident: hep28223-bib-0032-20241017 article-title: Bidirectional transport of amino acids regulates mTOR and autophagy publication-title: Cell doi: 10.1016/j.cell.2008.11.044 – volume: 130 start-page: 1120 year: 2007 ident: hep28223-bib-0003-20241017 article-title: Elucidation of a universal size‐control mechanism in Drosophila and mammals publication-title: Cell doi: 10.1016/j.cell.2007.07.019 – volume: 4 start-page: 52 year: 2012 ident: hep28223-bib-0018-20241017 article-title: Reconstruction of nuclear receptor network reveals that NR2E3 is a novel upstream regulator of ESR1 in breast cancer publication-title: EMBO Mol Med doi: 10.1002/emmm.201100187 – volume: 55 start-page: 1443 year: 2012 ident: hep28223-bib-0034-20241017 article-title: 65‐gene‐based risk score classifier predicts overall survival in hepatocellular carcinoma publication-title: Hepatology doi: 10.1002/hep.24813 – volume: 154 start-page: 84 year: 1999 ident: hep28223-bib-0042-20241017 article-title: TA1 oncofetal rat liver cDNA and putative amino acid permease: temporal correlation with c‐myc during acute CCl4 liver injury and variation of RNA levels in response to amino acids in hepatocyte cultures publication-title: Toxicol Appl Pharmacol doi: 10.1006/taap.1998.8555 – volume: 106 start-page: 151 year: 2015 ident: hep28223-bib-0036-20241017 article-title: TAZ regulates cell proliferation and epithelial‐mesenchymal transition of human hepatocellular carcinoma publication-title: Cancer Sci doi: 10.1111/cas.12587 – volume: 278 start-page: 33334 year: 2003 ident: hep28223-bib-0019-20241017 article-title: WW domain‐containing protein YAP associates with ErbB‐4 and acts as a co‐transcriptional activator for the carboxyl‐terminal fragment of ErbB‐4 that translocates to the nucleus publication-title: J Biol Chem doi: 10.1074/jbc.M305597200 – volume: 8 start-page: e75449 year: 2013 ident: hep28223-bib-0038-20241017 article-title: Increased expression of Yes‐associated protein 1 in hepatocellular carcinoma with stemness and combined hepatocellular‐cholangiocarcinoma publication-title: PLoS One doi: 10.1371/journal.pone.0075449 – volume: 29 start-page: 313 year: 2010 ident: hep28223-bib-0026-20241017 article-title: Q's next: the diverse functions of glutamine in metabolism, cell biology and cancer publication-title: Oncogene doi: 10.1038/onc.2009.358 – volume: 27 start-page: 255 year: 2010 ident: hep28223-bib-0041-20241017 article-title: The mTOR pathway is associated with the poor prognosis of human hepatocellular carcinoma publication-title: Med Oncol doi: 10.1007/s12032-009-9201-4 – volume: 5 start-page: 410 year: 2012 ident: hep28223-bib-0043-20241017 article-title: Differences in Yes‐associated protein and mRNA levels in regenerating liver and hepatocellular carcinoma publication-title: Mol Med Report – volume: 135 start-page: 1972 year: 2008 ident: hep28223-bib-0040-20241017 article-title: Pivotal role of mTOR signaling in hepatocellular carcinoma publication-title: Gastroenterology doi: 10.1053/j.gastro.2008.08.008 – volume: 25 start-page: 166 year: 2014 ident: hep28223-bib-0047-20241017 article-title: A peptide mimicking VGLL4 function acts as a YAP antagonist therapy against gastric cancer publication-title: Cancer Cell doi: 10.1016/j.ccr.2014.01.010 – volume: 14 start-page: 129 year: 2012 ident: hep28223-bib-0048-20241017 article-title: PI3K and mTOR signaling pathways in cancer: new data on targeted therapies publication-title: Curr Oncol Rep doi: 10.1007/s11912-012-0227-y – volume: 26 start-page: 1300 year: 2012 ident: hep28223-bib-0046-20241017 article-title: Genetic and pharmacological disruption of the TEAD‐YAP complex suppresses the oncogenic activity of YAP publication-title: Genes Dev doi: 10.1101/gad.192856.112 – volume: 107 start-page: 1431 year: 2010 ident: hep28223-bib-0009-20241017 article-title: Mammalian Mst1 and Mst2 kinases play essential roles in organ size control and tumor suppression publication-title: Proc Natl Acad Sci USA doi: 10.1073/pnas.0911409107 – volume: 11 start-page: 85 year: 2011 ident: hep28223-bib-0021-20241017 article-title: Regulation of cancer cell metabolism publication-title: Nat Rev Cancer doi: 10.1038/nrc2981 – volume: 30 start-page: 437 year: 1999 ident: hep28223-bib-0049-20241017 article-title: Inhibition of system A amino acid transport and hepatocyte proliferation following partial hepatectomy in the rat publication-title: Hepatology doi: 10.1002/hep.510300212 – volume: 34 start-page: 187 year: 1972 ident: hep28223-bib-0020-20241017 article-title: Regression models with life tables publication-title: J R Stat Soc doi: 10.1111/j.2517-6161.1972.tb00899.x – volume: 104 start-page: 275 year: 2013 ident: hep28223-bib-0013-20241017 article-title: Cancer metabolism: key players in metabolic reprogramming publication-title: Cancer Sci doi: 10.1111/cas.12085 – volume: 326 start-page: 174 year: 2005 ident: hep28223-bib-0031-20241017 article-title: Glutamine is a key regulator for amino acid‐controlled cell growth through the mTOR signaling pathway in rat intestinal epithelial cells publication-title: Biochem Biophys Res Commun – volume: 115 start-page: 4576 year: 2009 ident: hep28223-bib-0037-20241017 article-title: Yes‐associated protein is an independent prognostic marker in hepatocellular carcinoma publication-title: Cancer doi: 10.1002/cncr.24495 – volume: 22 start-page: 1962 year: 2008 ident: hep28223-bib-0023-20241017 article-title: TEAD mediates YAP‐dependent gene induction and growth control publication-title: Genes Dev doi: 10.1101/gad.1664408 – volume: 17 start-page: 2054 year: 2007 ident: hep28223-bib-0006-20241017 article-title: YAP1 increases organ size and expands undifferentiated progenitor cells publication-title: Curr Biol doi: 10.1016/j.cub.2007.10.039 – volume: 269 start-page: 3742 year: 2002 ident: hep28223-bib-0033-20241017 article-title: Signalling pathways and combinatory effects of insulin and amino acids in isolated rat hepatocytes publication-title: Eur J Biochem doi: 10.1046/j.1432-1033.2002.03069.x – volume: 58 start-page: 71 year: 2008 ident: hep28223-bib-0016-20241017 article-title: Cancer statistics, 2008 publication-title: CA Cancer J Clin doi: 10.3322/CA.2007.0010 – volume: 125 start-page: 1253 year: 2006 ident: hep28223-bib-0005-20241017 article-title: Identification and validation of oncogenes in liver cancer using an integrative oncogenomic approach publication-title: Cell doi: 10.1016/j.cell.2006.05.030 – volume: 13 start-page: 246 year: 2013 ident: hep28223-bib-0011-20241017 article-title: The Hippo pathway and human cancer publication-title: Nat Rev Cancer doi: 10.1038/nrc3458 – volume: 61 start-page: 191 year: 2015 ident: hep28223-bib-0015-20241017 article-title: Emerging trends in hepatocellular carcinoma incidence and mortality publication-title: Hepatology doi: 10.1002/hep.27388 – volume: 10 start-page: 671 year: 2011 ident: hep28223-bib-0012-20241017 article-title: Targeting cancer metabolism: a therapeutic window opens publication-title: Nat Rev Drug Discov doi: 10.1038/nrd3504 – volume: 87 start-page: 77 year: 2009 ident: hep28223-bib-0025-20241017 article-title: YAP, TAZ, and Yorkie: a conserved family of signal‐responsive transcriptional coregulators in animal development and human disease publication-title: Biochem Cell Biol – volume: 14 start-page: 1322 year: 2012 ident: hep28223-bib-0045-20241017 article-title: YAP mediates crosstalk between the Hippo and PI(3)K‐TOR pathways by suppressing PTEN via miR‐29 publication-title: Nat Cell Biol doi: 10.1038/ncb2615 – volume: 21 start-page: 886 year: 2007 ident: hep28223-bib-0002-20241017 article-title: Hippo signaling in organ size control publication-title: Genes Dev doi: 10.1101/gad.1536007 – volume: 436 start-page: 193 year: 2011 ident: hep28223-bib-0024-20241017 article-title: The role of amino acid transporters in inherited and acquired diseases publication-title: Biochem J doi: 10.1042/BJ20101912 – volume: 273 start-page: 14484 year: 1998 ident: hep28223-bib-0030-20241017 article-title: Amino acid sufficiency and mTOR regulate p70 S6 kinase and eIF‐4E BP1 through a common effector mechanism publication-title: J Biol Chem doi: 10.1074/jbc.273.23.14484 – volume: 31 start-page: 81 year: 2007 ident: hep28223-bib-0044-20241017 article-title: Activation of a system A amino acid transporter, ATA1/SLC38A1, in human hepatocellular carcinoma and preneoplastic liver tissues publication-title: Int J Oncol – volume: 8 start-page: 613 year: 2007 ident: hep28223-bib-0004-20241017 article-title: Filling out the Hippo pathway publication-title: Nat Rev Mol Cell Biol doi: 10.1038/nrm2221 – volume: 11 start-page: 447 year: 2014 ident: hep28223-bib-0017-20241017 article-title: HCC therapies—lessons learned publication-title: Nat Rev Gastroenterol Hepatol doi: 10.1038/nrgastro.2014.10 – volume: 116 start-page: 2465 year: 2015 ident: hep28223-bib-0035-20241017 article-title: Functional and clinical evidence that TAZ is a candidate oncogene in hepatocellular carcinoma publication-title: J Cell Biochem doi: 10.1002/jcb.25117 – volume: 18 start-page: 5537 year: 2012 ident: hep28223-bib-0014-20241017 article-title: Targeting cancer metabolism publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-12-2587 – volume: 737 start-page: 267 year: 1983 ident: hep28223-bib-0029-20241017 article-title: The regulation of neutral amino acid transport in mammalian cells publication-title: Biochim Biophys Acta doi: 10.1016/0304-4157(83)90003-5 – volume: 34 start-page: 702 year: 2013 ident: hep28223-bib-0050-20241017 article-title: Solute carriers as drug targets: current use, clinical trials and prospective publication-title: Mol Aspects Med doi: 10.1016/j.mam.2012.07.015 |
SSID | ssj0009428 |
Score | 2.5226626 |
Snippet | Metabolic activation is a common feature of many cancer cells and is frequently associated with the clinical outcomes of various cancers, including... UNLABELLEDMetabolic activation is a common feature of many cancer cells and is frequently associated with the clinical outcomes of various cancers, including... |
SourceID | proquest pubmed crossref wiley |
SourceType | Aggregation Database Index Database Enrichment Source Publisher |
StartPage | 159 |
SubjectTerms | Adaptor Proteins, Signal Transducing - genetics Adaptor Proteins, Signal Transducing - physiology Amino Acid Transport Systems - physiology Amino acids Animals Carcinoma, Hepatocellular - genetics Carcinoma, Hepatocellular - metabolism Cell growth Cell proliferation Female Gene Expression Regulation, Neoplastic Hepatocellular carcinoma Hepatology Humans Intracellular Signaling Peptides and Proteins - physiology Liver cancer Liver Neoplasms - genetics Liver Neoplasms - metabolism Mechanistic Target of Rapamycin Complex 1 Metabolic activation Metabolic pathways Metabolic rate Metabolism Mice Multiprotein Complexes - physiology Phosphoproteins - genetics Phosphoproteins - physiology Protein Structure, Tertiary Rapamycin Signal Transduction TOR protein TOR Serine-Threonine Kinases - physiology Trans-Activators Transcription Transcription Factors Tumor suppressor genes Tumorigenesis Yes-associated protein |
Title | Yes‐associated protein 1 and transcriptional coactivator with PDZ‐binding motif activate the mammalian target of rapamycin complex 1 pathway by regulating amino acid transporters in hepatocellular carcinoma |
URI | https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fhep.28223 https://www.ncbi.nlm.nih.gov/pubmed/26389641 https://www.proquest.com/docview/1750418010 https://www.proquest.com/docview/1919424393 https://www.proquest.com/docview/1751489019 https://www.proquest.com/docview/1776664589 |
Volume | 63 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwELaqHhAX3o9CqQziwCXbOLGziTgh2moBFVWISgUhRX6MYQVJqn0Ay4mfwG_jJ_BLmHEeVaEgxG2lzHjHyYz92R5_w9h94YWwjmhDhYJIKpVFJlZJlCKai7WCOHV0orv_PJscyqdH6miNPezvwrT8EMOGG0VGGK8pwLWZb5-Qhr6D4xHlQBLTp0gz4s3feXFCHVXIUFcVV10xnS4XPatQnGwPmqfnot8A5mm8GiacvYvsTW9qm2fyfrRcmJH98guL43_25RK70AFR_qj1nMtsDeor7Nx-d9R-lX1_BfMfX7_p7vOB44HSYVpzwXXt-IImuX7IwYZsQ1ckPtIantPmLj_YeY36ZhquzXDK-fO8EwGOsJNXuqrCLgtv09F54znVY69WaAEPue7wGf-NiiZ_0ituVnwGb0O5MWxQV9O6wQannSmBoH0256iK_UQz6EiCcmy5pXJJdVPpa-xwb_fl40nUFYCILAHLyMXWJilo7bwFY6R2iVQ4U1CdybgwPh8nHlKvCq9zL32aG6GdSsYQWOVcml5n63VTw03GLcrmoMUYByjpwRUxaisDhSlyqyRssAe9K5S2Y0enIh0fypbXOSnR9jJ8ow12bxA9bilBzhLa7P2p7EaFeSmIS18gJojPflwI9FpEiKh9d3iM4U4vTNfQLEMTuIBFEFf8TWaMi1KpcpS50bryYGhCCDWTAvsbHPLPPSgnuwfhx61_F73NziOgzChHL0k32fpitoQ7CNoWZguj88mzrRCjPwFi7EUY |
linkProvider | Wiley-Blackwell |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3bbtQwELVKkYAX7pdCAYN44CXbOLF3E4kXBK0W6FYVaqWChCJfxrCCJNVegOWJT-Db-AS-hBkn2apQEOJtpcx4x8nYPh6PzzD2QHghrCPaUKEgkkr1IxOrJEoRzcVaQZw6OtEd7fSH-_L5gTpYYY-6uzANP8Qy4EYjI8zXNMApIL1xxBr6Dg57lASZnmKnw_kcQaKXR-RRuQyVVXHfFdP5ct7xCsXJxlL1-Gr0G8Q8jljDkrN1gb3pjG0yTd735jPTs19-4XH8395cZOdbLMofN85zia1AdZmdGbWn7VfY91cw_fH1m26_IDgeWB3GFRdcV47PaJ3rZh1syNZ0S-IjbeM5xXf57tPXqG_G4eYMp7Q_z1sR4Ig8eanLMgRaeJORzmvPqSR7uUALeEh3h8_4b1Q3-ZNecLPgE3gbKo5hg7ocVzU2OG5NCRztkylHVewnmkGnEpRmyy1VTKrqUl9l-1ube0-GUVsDIrKELSMXW5ukoLXzFoyR2iVS4WJBpSbj3PhskHhIvcq9zrz0aWaEdioZQCCWc2l6ja1WdQU3GLcom4EWA5yjpAeXx6itDOQmz6ySsMYedr5Q2JYgnep0fCgaauekQNuL8I3W2P2l6GHDCnKS0HrnUEU7MUwLQXT6AmFBfPLjXKDbIkhE7XvLxzji6YXpCup5aAL3sIjj8r_JDHBfKlWGMtcbX14amhBI7UuB_Q0e-eceFMPN3fDj5r-L3mVnh3uj7WL72c6LW-wc4ss2YrXOVmeTOdxGDDczd8JQ_QnQP0g3 |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3bbtQwELVKkSpeuFMKBQzigZds48TejcUTol0tl1YrRKWCkCJfYQVJVnsBlic-gW_jE_gSZpxLVSgI8bZSZrzjZOw5tsdnCLnPPGPGIm0oEy7iQvQjHYskSgHNxUq4OLV4ort_0B8d8qdH4miNPGzvwtT8EN2GG46MMF_jAJ9av3NMGvrOTXuYA5meIWd5H8IkIqIXx9xRkofCqrDsivF4Wba0QnGy06meDEa_IcyTgDVEnOEF8qa1tU40ed9bLnTPfPmFxvE_O3ORnG-QKH1Uu84lsubKy2Rjvzlrv0K-v3LzH1-_qeb7OUsDp8OkpIyq0tIFRrl2zoGGTIV3JD7iIp7i7i4d774GfT0J92YoJv152og4CriTFqoowjYLrfPRaeUpFmQvVmABDcnu7jP8G1ZN_qRWVK_ozL0N9cagQVVMygoanDSmBIb22ZyCKvQTzMAzCUyypQbrJZVVoa6Sw-Hey8ejqKkAERlElpGNjUlSp5T1xmnNlU24gFCBhSZjqX02SLxLvZBeZZ77NNNMWZEMXKCVs2l6jayXVemuE2pANnOKDWCG4t5ZGYO20E5qmRnB3RZ50LpCbhp6dKzS8SGviZ2THGzPwzfaIvc60WnNCXKa0HbrT3kzLcxzhmT6DEBBfPpjycBrASKC9t3uMYx3fGGqdNUyNAErWEBx8m8yA1iVcpGBzGbtyp2hCULUPmfQ3-CQf-5BPtobhx83_l30DtkY7w7z508Ont0k5wBcNttV22R9MVu6WwDgFvp2GKg_AdP9RuY |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Yes-associated+protein+1+and+transcriptional+coactivator+with+PDZ-binding+motif+activate+the+mammalian+target+of+rapamycin+complex+1+pathway+by+regulating+amino+acid+transporters+in+hepatocellular+carcinoma&rft.jtitle=Hepatology+%28Baltimore%2C+Md.%29&rft.au=Park%2C+Yun-Yong&rft.au=Sohn%2C+Bo+Hwa&rft.au=Johnson%2C+Randy+L&rft.au=Kang%2C+Myoung-Hee&rft.date=2016-01-01&rft.eissn=1527-3350&rft.volume=63&rft.issue=1&rft.spage=159&rft_id=info:doi/10.1002%2Fhep.28223&rft_id=info%3Apmid%2F26389641&rft.externalDocID=26389641 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0270-9139&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0270-9139&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0270-9139&client=summon |